4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.63 Average PT from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have earned an average recommendation of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $30.63.

A number of research firms recently issued reports on FDMT. Morgan Stanley lowered their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Monday, January 13th. BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Chardan Capital lowered their target price on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Leerink Partners lowered their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, March 7th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in FDMT. KLP Kapitalforvaltning AS bought a new position in 4D Molecular Therapeutics during the 4th quarter worth $48,000. Point72 Asia Singapore Pte. Ltd. bought a new position in 4D Molecular Therapeutics during the 4th quarter worth $50,000. PNC Financial Services Group Inc. increased its position in 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after buying an additional 3,630 shares during the period. Daiwa Securities Group Inc. increased its position in shares of 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock worth $55,000 after purchasing an additional 9,737 shares during the period. Finally, Velan Capital Investment Management LP bought a new position in shares of 4D Molecular Therapeutics in the fourth quarter worth $56,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $3.92 on Monday. The stock’s fifty day moving average price is $4.69 and its two-hundred day moving average price is $7.49. 4D Molecular Therapeutics has a 52-week low of $3.58 and a 52-week high of $36.25. The company has a market cap of $181.50 million, a price-to-earnings ratio of -1.38 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). On average, equities analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.